Related Articles
Response to 223Ra-dichloride in castration-resistant prostate cancer with bone metastasis: A case report
Timing of changing therapy from gemcitabine and cisplatin chemotherapy based on real‑world data of advanced urothelial carcinoma
A randomized phase III trial of personalized peptide vaccination for castration‑resistant prostate cancer progressing after docetaxel
Pretreatment fibrinogen levels are associated with survival outcome in patients with cancer using immunotherapy as a second‑line treatment
Docetaxel-based therapy with and without antiangiogenic agents as first-line chemotherapy for castration-resistant prostate cancer: A meta-analysis of nine randomized controlled trials